-
Mashup Score: 3FDA Approves Sotorasib/Panitumumab in KRAS G12C-Mutated CRC - 6 hour(s) ago
Results from the CodeBreaK 300 trial helped lead to the approval of sotorasib/panitumumab in KRAS G12C-mutated CRC.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1
The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
.@US_FDA has approved acalabrutinib plus bendamustine and rituximab in previously untreated MCL. #lymsm | @FDAOncology @LymphClinician https://t.co/6j8g3Xei8O https://t.co/NDQSTq1BGn
-
-
Mashup Score: 0
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
“Patients with BCG-naïve high-risk [NMIBC] have high rates of recurrence and progression. These study results demonstrate the potential for sasanlimab in combination with BCG to redefine the treatment paradigm...” said Neal Shore, MD, FACS. #blcsm https://t.co/CqSNDucvOU
-
-
Mashup Score: 0FDA Receives NDA for TAR-200 in BCG-Unresponsive High-Risk NMIBC - 11 hour(s) ago
Data from the phase 2b SunRISe-1 study support the NDA for TAR-200 in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer with CIS.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Johnson & Johnson has launched the submission of a new drug application for TAR-200 as a treatment for those with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ. #blcsm https://t.co/GyvPpWMNJ3 https://t.co/VBVWJmg2DC
-
-
Mashup Score: 0Medical Oncologist - Antioch, CA at Sutter East Bay Medical Group - 14 hour(s) ago
Sutter East Bay Medical Group (SEBMG) is seeking an experienced collaborative medical oncologist to be part of our growing team. Sutter is expanding services to cancer patients in the East Bay Market, one of six market areas for Sutter Health. SEBMG currently employs five medical oncologists in our Berkeley based cancer center and, to better serve our community, we plan to add medical oncology care and infusion services to a new location in Antioch, California in the summer of 2024. This site will be one
Source: cancer-network.myjboard.ioCategories: General Medicine News, Oncologists1Tweet-
Join the Growing Team at Sutter East Bay Medical Group! @SutterHealth is expanding cancer care services in the East Bay market and is seeking an experienced medical oncologist to join their team. Apply now: https://t.co/A5J5stjTWy https://t.co/4RYLzavN06
-
-
Mashup Score: 0
The NeXT Personal platform identified minuscule amounts of ctDNA that were found to be predictive of OS and RFS outcomes in patients with lung adenocarcinoma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
ctDNA status was predictive of OS in patients with lung adenocarcinoma (ctDNA low: HR, 11.08, 95% CI, 1.48-83.2; ctDNA high: HR, 19.33; 95% CI, 2.56-146.0) and RFS (low: HR, 14.17, 95% CI, 1.91–105.3; high: HR, 25.79, 95% CI, 3.48–191.4). #lcsm https://t.co/kjd7gin6Cm
-
-
Mashup Score: 0LOAd703 Receives FDA Fast Track Designation for Pancreatic Cancer - 17 hour(s) ago
The decision follows safety data from the phase 1/2 LOKON001 trial evaluating LOAd703 in advanced pancreatic ductal adenocarcinoma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The decision follows data from the phase 1/2 LOKON001 trial, which evaluated the therapy in combination with nab-paclitaxel and gemcitabine with or without atezolizumab. #pancsm | @FDAOncology @US_FDA https://t.co/ZGU8gsonVO
-
-
Mashup Score: 0
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells. #kicsm | @kidneycan https://t.co/4Yi1X0SJ3S
-
-
Mashup Score: 0
The use of artificial intelligence led to a higher rate of breast cancer detection as an improvement for mammography screening compared with standard detection methods.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The breast cancer detection rate was 6.7 per 1000 women screened, which was a relative increase of 17.6% (95% CI, +5.7% to +30.8%) and statistically superior to the 5.7 per 1000 rate that was detected in the control group. #bcsm #AI https://t.co/F8llxfuuAL
-
-
Mashup Score: 0
Investigators are assessing treatment with ELC-100 among patients with pancreatic neuroendocrine tumors as part of a phase 1/2 trial.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has granted orphan drug designation to ELC-100, an investigational oncolytic virus, as a treatment for patients with pancreatic neuroendocrine tumors. #pancsm | @FDAOncology @FDAOncology https://t.co/D71lweQ5zR
-
The FDA has approved sotorasib plus panitumumab for patients with KRAS G12C-mutated metastatic colorectal cancer. #gicsm | @FDAOncology https://t.co/ywRrxAyL11